cbdMD, Inc.

YCBD

US12482W4087

Pharmaceuticals

Delayed Nyse Other stock markets 04:00:00 2025-06-18 pm EDT			5-day change	1st Jan Change
0.8380 ^USD	+1.93%		-4.99%	-72.07%

May. 15	CbdMD, Inc., Q2 2025 Earnings Call, May 15, 2025
May. 15	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI

CbdMD, Inc Announces Resignation of Mark Elliott as Chief Operating Officer, effective October 01, 2020

Published on 09/21/2020 at 06:03

cbdMD, Inc. announced that resignation of Mark Elliott as Chief Operating Officer, with effect from October 01, 2020.

Latest news about cbdMD, Inc.

CbdMD, Inc., Q2 2025 Earnings Call, May 15, 2025	May. 15
CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	May. 15	CI
CbdMD, Inc. Elects Directors	Apr. 11	CI
CbdMD, Inc., Q1 2025 Earnings Call, Feb 13, 2025	Feb. 13
CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024	Feb. 13	CI
CbdMD, Inc. Appoints T. Ronan Kennedy to Its Board of Directors	Dec. 23	CI
CbdMD, Inc., Q4 2024 Earnings Call, Dec 18, 2024	Dec. 18
CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024	Dec. 18	CI
CbdMD, Inc. Auditor Raises 'Going Concern' Doubt	Dec. 17	CI
Earnings Flash (YCBD) CBDMD Reports Q3 Revenue $5.2M	24-08-14	MT
CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	24-08-14	CI
Earnings Flash (YCBD) CBDMD Reports Q2 Revenue $4.4M	24-05-15	MT
CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	24-05-15	CI
CbdMD, Inc. Appoints Brad Whitford as Chief Accounting Officer, Treasurer and Secretary	24-04-02	CI
CbdMD, Inc. - Shareholder/Analyst Call	24-03-29
Earnings Flash (YCBD) CBDMD Posts Q1 Revenue $5.4M	24-02-13	MT
CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	24-02-13	CI
CbdMD, Inc. announced that it expects to receive $1.25 million in funding	24-01-29	CI
Earnings Flash (YCBD) CBDMD Posts Q4 Revenue $24.2M	23-12-22	MT
CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	23-12-22	CI
CbdMD, Inc. Auditor Raises 'Going Concern' Doubt	23-12-21	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	23-12-20	DJ
North American Morning Briefing : Traders Await -2-	23-12-13	DJ
Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	23-10-05	MT
CbdMD, Inc. - Shareholder/Analyst Call	23-09-22

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 12 - Q3 2025 Earnings Release (Projected)

More about the company